Inovio Pharmaceuticals DNA vaccine

Un vaccino per hiv a base di Dna, della Inovio Pharmaceuticals, in sperimentazione:

[Devi essere iscritto e connesso per vedere questo link]
Inovio Pharmaceuticals' Novel DNA Vaccine for Clade C HIV Achieves Immune Responses and Protection in Non-Human Primates

Share




Significant T-cell and antibody responses demonstrate the potential of PENNVAX™ DNA vaccines delivered using electroporation


BLUE BELL, Pa.--(BUSINESS WIRE)--Jan 10, 2011 - Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C viruses in the journal Vaccine. Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China, and there is a critical need for a vaccine targeted to these areas.

The study, conducted by Inovio scientists and their collaborators, is described in the published paper, entitled "High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.” In this study, the vaccine induced strong antibody and T-cell immune responses in rhesus monkeys. Furthermore, the vaccinated monkeys displayed protective effects against a subsequent challenge with an infectious dose of SHIV virus (chimeric HIV/SIV virus) compared to the placebo control animals. These results further support the proof of concept for Inovio's global DNA vaccine candidates, PENNVAX™-G (vaccine against HIV Clades A, C, and D) and PENNVAX™-GP (vaccine against HIV Clades A, B, and C) in a relevant preclinical model. PENNVAX™-G is currently being tested in a 92-patient global Phase I clinical study (RV-262) conducted by the U.S. Military HIV Vaccine Research Program (MHRP). PENNVAX-GP is being developed using a multi-year $23.5 million NIAID HIV vaccine development contract awarded to Inovio.

Inovio recently announced interim immunogenicity and safety data from its Phase I clinical study of PENNVAX™-B, a DNA vaccine for the prevention of HIV Clade B infection. PENNVAX-B achieved high vaccine-induced response rates and strong magnitude of T-cell immune responses in vaccinated subjects. Similar to reported results from a Phase I clinical study of Inovio's therapeutic DNA vaccine for cervical cancer, the response rates and magnitude of responses achieved in this study were significantly higher than those seen previously with other DNA vaccine trials. Complete immunogenicity data as well as end-of-study safety data from the PENNVAX-B study are expected in 2Q 2011.

Dr. J. Joseph Kim, Inovio's president and CEO, said: “In the past year, we were able to demonstrate best-in-class clinical immunogenicity data from our DNA vaccines for cervical cancer and HIV. We look forward to advancing our cervical cancer candidate into Phase II studies this quarter and completing the preventive HIV study in the next quarter. The data from this study is supportive of the ongoing Phase I clinical program, under the RV-262 protocol, and we are excited about the significant preclinical progress of our PENNVAX-GP global HIV vaccine program. These results further support the prospect that Inovio's DNA vaccine and delivery platform could play an important role in developing new vaccines and therapies for major diseases like HIV.”

Inovio's PENNVAX-G vaccine is currently being tested in 12 HIV-uninfected participants in the U.S. Once the vaccine has been assessed as safe and acceptable, the study will expand to three additional global MHRP sites: Kericho, Kenya; Kampala, Uganda; Mbeya, Tanzania. Healthy, HIV-uninfected participants will be enrolled at each of these sites for a total of 80 international participants.

IND-enabling preclinical work for PENNVAX-GP will be conducted in 2011 and the Phase I study is planned to be initiated in 2012.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV-caused cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at [Devi essere iscritto e connesso per vedere questo link]

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.





Contact: Inovio Pharmaceuticals
Bernie Hertel, 858-410-3101 (Investors)
[Devi essere iscritto e connesso per vedere questo link]
or
Richardson & Associates
Jeff Richardson, 805-491-8313 (Media)
[Devi essere iscritto e connesso per vedere questo link]

HCV?!

ho visto ke hai cambiato il titolo.

meno male perke' pensavo di aver capito male l'articolo.

mi fa piacere che leggi con attenzione quello che posto..

La Inovio farmaceutici dara' alcune comunicazioni sui vaccini a base di Dna in sperimentazione al congresso:
31st Annual Health Care Conference che si terra' il 7-9 marzo al Boston Marriott Copley Place in Boston, MA.

[Devi essere iscritto e connesso per vedere questo link]

Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference

Share



BLUE BELL, Pa., Feb. 24, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO will present a company overview at the Cowen & Co. 31st Annual Health Care Conference being held March 7-9 at the Boston Marriott Copley Place in Boston, MA.



Inovio Presentation: March 9, 2011 at 8:00 am EST

[Devi essere iscritto e connesso per vedere questo link]

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at [Devi essere iscritto e connesso per vedere questo link]

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 [Devi essere iscritto e connesso per vedere questo link]

Media: Jeff Richardson, Richardson & Associates 805-491-8313 [Devi essere iscritto e connesso per vedere questo link]





(Logo: [Devi essere iscritto e connesso per vedere questo link]

SOURCE Inovio Pharmaceuticals, Inc.

CONTACT: Investors, Bernie Hertel of Inovio Pharmaceuticals, +1-858-410-3101, [Devi essere iscritto e connesso per vedere questo link], or Media, Jeff Richardson of Richardson & Associates +1-805-491-8313, [Devi essere iscritto e connesso per vedere questo link]

Il vaccino della Inovio potrebbe ampliare il suo utilizzo per curare anche altre patologie animali.

[Devi essere iscritto e connesso per vedere questo link]

Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
Strong immune responses achieved in first target animal tested with SynCon™ foot-and-mouth disease DNA vaccine
Share

By Inovio Pharmaceuticals, Inc.
Published: Wednesday, Mar. 2, 2011 - 1:11 am

BLUE BELL, Pa., March 2, 2011 -- /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it achieved compelling results in a study of its DNA vaccine for foot-and-mouth disease administered by Inovio's proprietary vaccine delivery technology. The preclinical data was highlighted by Dr. Niranjan Y. Sardesai, Inovio's Sr. VP of Research and Development, at the Vaccine World Summit being held in New Delhi, India, March 1–3. The presentation, entitled "Electroporation Mediated Delivery of DNA Vaccines: Translating the Promise to Prophylactic Vaccination," focused on Inovio's recent developments to advance novel vaccines for several emerging pathogens, including foot-and-mouth disease (FMD), Chikungunya, and dengue viruses.

The FMD virus is one of the most infectious diseases affecting farm animals including cattle, swine, sheep and goats, and is a serious threat to global food safety. Once an area is exposed to FMD, livestock & dairy exports are ceased and herds are culled. For example, in a major FMD outbreak in the UK in 2001, more than 4 million animals were slaughtered, resulting in more than $10 billion (USD) in economic losses. In a current FMD epidemic in South Korea, more than 3.3 million animals, mostly swine, have been culled in an attempt to keep the disease from spreading.

Because FMD can spread rapidly and beyond regional boundaries there is a need to develop vaccines that can simultaneously target different regional serotypes of FMD in a single vaccine. Inovio's SynCon™ technology enables rapid development of vaccines that can cover multiple serotypes simultaneously with a single formulation. Inovio, its subsidiary, VGX Animal Health (VAH), and its academic collaborators generated and tested SynCon™ DNA vaccine constructs targeting all seven main FMD virus serotypes, moving from antigen design to large animal testing in only a few months.

In a study conducted in pigs, just a single vaccination with an Inovio FMD vaccine comprising four of the most common FMD serotypes generated high titer, antigen-specific antibody responses for each serotype in the vaccinated animals. The responses were boosted even higher with a second immunization. High levels of T-cell responses were also measured in the vaccinated animals. All vaccines were administered intramuscularly with Inovio's CELLECTRA® electroporation delivery system.

There are several potential advantages of Inovio's FMD DNA vaccine:

Inovio's SynCon™ DNA vaccine cannot cause disease, which is a possibility using current killed viral FMD vaccines due to incomplete virus inactivation. This limits current vaccination to herds that may be imminently exposed to FMD. Inovio's vaccine would permit truly preventive vaccination.
Inovio's SynCon™ universal vaccine is designed to generate broader, cross-protective immune responses across different FMD serotypes, unlike existing vaccines that must be matched to the FMD serotype.
Current FMD vaccines display the same multiple proteins as the actual virus. Healthy vaccinated animals can therefore not be distinguished from infected animals, frequently leading to the slaughter of uninfected herds. Inovio's SynCon vaccine is encoded for a single antigen (VP1 protein) common across FMD serotypes. Because it is a synthetic consensus antigen unmatched to naturally existing FMD strains, a blood test can distinguish non-infected vaccinated animals from naturally infected animals. This could potentially reduce the slaughter of healthy animals in outbreak areas.
Better thermal stability of Inovio's product overcomes the challenge of expensive and/or unavailable cold storage and transport in developing countries at high risk of FMD outbreaks.


Dr. J. Joseph Kim, Inovio's President and CEO, said: "Foot-and-mouth pandemics are a great threat to global food supply and society. Recent outbreaks in Europe and Asia have wreaked havoc in those areas and caused billions of dollars worth of damage. We at Inovio and VGX Animal Health are extremely pleased with the advancement of our new SynCon™ DNA vaccine for FMD through large animal pilot testing and we look forward to the further development of this important vaccine."

About Foot-and-Mouth Disease

Foot-and-mouth disease (FMD) affects cloven-hoofed animals such as cattle, pigs, sheep, goats and water buffalo, and is capable of rapidly infecting large numbers of animals. Seven main types of FMD virus are believed to exist today. Like other viruses, the FMD virus continually evolves and mutates. To date there has been no cross-protection between strains even within the different types of FMD virus. Vaccine viruses which are not completely killed have resulted in FMD outbreaks, hence vaccines used today are administered to the herd only once an outbreak is detected in an area in order to limit the rapid spread of infection, thus limiting the potential utility of such vaccines.

While death rates are generally low, the highly infectious nature of the virus has a profound negative economic impact, such as in the dairy industry where cattle may experience reduced milk production, poor growth and permanent hoof damage. An FMD outbreak typically leads to economic sanctions, including the loss of export markets, and can negatively impact tourism as restrictions are placed on the movement of people and animals. This was the case in the 2001 outbreak in the UK.

About VGX Animal Health, Inc.

VGX Animal Health is developing DNA-based therapies for food and companion animals utilizing proprietary plasmid-based DNA delivery and expression technology to optimize an animal's natural biological and immunological potential. The company is a majority-owned subsidiary of Inovio Pharmaceuticals, Inc.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at [Devi essere iscritto e connesso per vedere questo link]

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 [Devi essere iscritto e connesso per vedere questo link]
Media: Jeff Richardson, Richardson & Associates 805-491-8313 [Devi essere iscritto e connesso per vedere questo link]



(Logo: [Devi essere iscritto e connesso per vedere questo link]

SOURCE Inovio Pharmaceuticals, Inc.

Il vaccino a DNA della Inovio Pharmaceuticals protegge contro l'HIV in primati non umani.

Due riviste scientifiche pubblicano i dati che mostrano una robusta, e sostenuta risposta delle cellule T grazie al vaccino a DNA della Inovio.

Nuovi dati di uno studio preclinico del vaccino SynCon DNA ™ contro l'HIV sono stati pubblicati in due riviste scientifiche separate.

Negli animali vaccinati, gli studi hanno dimostrato la capacità del vaccino contro l'HIV della Inovio di sfruttare il sistema immunitario, generando risposte importanti e significative delle cellule T antigene-specifiche nonche' la protezione dal virus.

I risultati sono stati pubblicati in due riviste con co-autori dei ricercatori Inovio e collaboratori accademici: la rivista "Vaccine" titola "L'immunogenicità di un ceppo HIV-1 tipo C sintetico basato sul vaccino a DNA di envelope";

PLoS uno ha pubblicato invece l'articolo "programmazione a lungo termine di immunità antigene-specifica da espressione genica in PBMC di macachi rhesus immunizzati con un vaccino a DNA SIV".

Nel primo studio, i ricercatori hanno creato un vaccino di sintesi, ottimizzato a DNA per una proteina envelope (di superficie) di HIV tipo C, utilizzando il processo di progettazione del vaccino detto : SynCon Inovio ™.

I processi di ottimizzazione sono stati condotti tra codone/RNA di ottimizzazione, e l'aggiunta di una sequenza di Kozak con la sequenza leader di IgE per migliorare l'espressione del vaccino sugli esseri umani.

Lo sviluppo di un vaccino per il tipo C è considerata una priorità molto alta dal momento che questo sottotipo di virus HIV è il più diffuso in molte parti dell'Africa, dell'India e della Cina.

La risposta nei test di questo vaccino ha generato elevati livelli di risposte delle cellule T che sono stati fino a tre volte maggiori rispetto le risposte delle cellule T da altri vaccini a DNA costruiti con targeting envelope HIV. Due studi di fase I umani metteranno alla prova l'immunogenicità del vaccino nei volontari negli Stati Uniti e in Africa.

Nel secondo studio, i ricercatori hanno valutato gli effetti protettivi del vaccino a DNA "PENNVAX ™" della Inovio usando un vaccino per il virus dell' HIV delle scimmie chiamato SIV (virus dell'immunodeficienza delle scimmie).
Il vaccino è stato codificato per le tre principali proteine (antigeni gag, pol e env ) codificati all'interno del genoma retrovirale ed è stato iniettato con la tecnica dell'elettroporazione di proprietà Inovio , con tecnologia (EP).

I ricercatori hanno valutato il trattamento con un' analisi genica detta microarray ossia con test immunologici standard e test flow-based di attivazione.

Essi hanno osservato sequenze di geni diversi che sono stati regolati in modo differenziato e il vaccino ha protetti il gruppo degli animali vaccinati rispetto agli animali non vaccinati.
L'analisi microarray e' usata per testare gli effetti del vaccino a DNA, ha dimostrato che la vaccinazione PENNVAX Inovio ha portato alla maggiore produzione di sequenze di geni, tra cui quelli coinvolti nella segnalazione dell'interferone così come quelli coinvolti nel movimento delle cellule immunitarie e la progressione del ciclo cellulare.
Questi risultati sono rilevanti per l'uomo perché la comprensione di questi meccanismi potrebbe fornire una migliore comprensione dei modi in cui la risposta immunitaria potrebbe proteggere gli individui immunizzati con vaccino PENNVAX dall' infezione e dalla propagazione del virus e può aiutare inoltre nella ottimizzazione dei candidati vaccini della Inovio contro l'HIV attualmente in vari studi clinici.

Lo studio inoltre ha ha dimostrato che le scimmie rhesus vaccinate erano protetti da una successiva iniezione del virus SIV (HIV-equivalente in primati non umani) gli animali vaccinati infatti hanno dimostrato un forte controllo della replicazione virale e la carica virale era più bassa.
Anche le cellule T killer antigene-specifiche hanno avuto risposte piu alte , un risultato che Inovio ha osservato in diversi studi precedenti preclinici e clinici.
In confronto, gli animali non vaccinati non sono riusciti a controllare l'infezione da virus SIV.
Le cellule T CD8 + killer sono fondamentali nel combattere le cellule cancerose o infette presenti nel corpo e sono indispensabili per raggiungere una risposta sufficiente ai nuovi vaccini contro i tumori e contro le malattie croniche infettive come l'HIV e l'epatite C.
...

Ulteriori risultati incoraggianti per il vaccino della Inovio, Pennavax attualmente in fase 1.
Attualmente ha dimostrato una buona risposta anticorpale.
Continuano gli arruolamenti di pazienti per la fase successiva in tre paesi dell'africa.


Inovio Pharma (INO) Reports Encouraging Results for HIV Vaccine PENNVAX-G Following Phase I

More News related to INO
Inovio Pharma (INO) Reports Encouraging Results for HIV Vaccine PENNVAX-G Following Phase I
Inovio Pharmaceuticals' PENNVAX™-G Global HIV Vaccine Plus MVA Boost Achieves 100% Antigen-Specific T-Cell Immune Responses in Interim Phase I Data
Inovio Pharmaceuticals to Present at Scientific Conferences
Inovio Pharma (INO) Files $75M Mixed Shelf
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
More News related to INO



More News related to Corporate News
Jacobs Engineering Group (JEC) Awarded $2.3 Million Contract from Hudson County Improvement Authority
Jacobs Engineering (JEC) Announces $125 Million Contract From U.S. Special Operations Command
Omeros Corp. (OMER) Identify 4 Additional Orphan G Protein-Coupled Receptors
Universal Forest Products (UFPI) to Consolidate into Two Geographic Divisions
TASER Int'l (TASR) Gets Large Order for X26 ECDs from U.S. Agency
More News related to Corporate News


September 13, 2011 7:11 AM EDT

Inovio Pharmaceuticals, Inc. (AMEX: INO), reports that early data from a Phase I study assessing its PENNVAX-G global HIV vaccine plus a virus vector vaccine, Modified Vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR), as a unique prime-boost preventive HIV vaccination strategy has demonstrated strong immune responses and safety.

This interim data was from the first cohort of 11 healthy subjects enrolled in the US as part of the first phase of the study to assess safety of the prime-boost combination vaccine. Enrollment will now continue in three sites in Africa in the next phase of the study.

From the release: "Early analysis of this initial data revealed a strong cell-mediated immune response, with CD4+ and CD8+ T cells specific for both the gag and env antigens encoded by the prime and boost agents. Significantly, anti-env CD4+ T-cell immune responses were noted in 100% (11 of 11) of evaluated subjects and CD8+ T-cell responses were noted in 45% (5 of 11) of evaluated subjects after the first MVA boost following the two DNA vaccinations. The env specific CD4+ and CD8+ T-cell response rates were noted to be 73% (8 of 11) and 45% (5 of 11) respectively after the second MVA boost."

La Inovio farmaceutici ha ricevuto un premio per migliore ricerca sui vaccini, al 5 th Global Vaccine Congress di Seattle, per i vaccini anti HIV AIDS e anti Cancro a base di DNA della Inovio in sperimentazione.
Questo testimonia l'importanza di questi vacciniin sperimentazione.


Oct. 5, 2011, 4:00 a.m. EDT
Inovio Pharmaceuticals' Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
Therapeutic Vaccine Against Cervical Dysplasias and Cancer Wins First Prize in Edward Jenner Award Competition




BLUE BELL, Pa., Oct. 5, 2011 /PRNewswire via COMTEX/ -- Inovio Pharmaceuticals, Inc. INO
+0.10% , a leader in the
development of synthetic vaccines against cancers and infectious diseases, announced today that the company's research to develop a therapeutic synthetic vaccine for cancer won the Edward Jenner Poster Award First Prize at the recent 5th Vaccine and ISV Global Congress. This prestigious prize recognizes the most promising research at the Congress. Inovio's poster, entitled "Induction of HPV specific CTLs in human volunteers after DNA immunization," was selected from over 500 abstracts by the scientific organizing committee and an expert panel of judges. The award citation highlighted Inovio's pioneering therapeutic cervical dysplasia/cancer vaccine program and the novel assay for determining vaccine impact.

The Vaccine Congress is a forum for a state-of-the-art report on the latest progress in the development of vaccines for infectious and non-infectious diseases. The annual Jenner Award is named after Edward Jenner (1749-1823), who is widely credited as the pioneer of the smallpox vaccine and is often referred to as the "Father of Immunology."

Inovio presented data showing the development of a novel flow cytometry-based assay to assess cytolytic T cell (CTL) activity in immunized patients. Blood samples collected from subjects immunized with Inovio's SynCon® therapeutic HPV 16 and 18 vaccine (VGX-3100) were analyzed by the new assay. Inovio previously announced the results of its Phase I clinical trial demonstrating the induction of strong T-cell immune responses to the vaccine. An important aspect of a therapeutic vaccine is its ability to generate antigen-specific cytolytic CD8+ T cells that can kill infected host cells. Using the new assay, Inovio scientists were able to demonstrate for the first time that the vaccines developed fully functional CTLs capable of killing targets in an antigen-specific manner -- a finding that may prove crucial to the success of an effective therapy for HPV-related disease.

Dr. J. Joseph Kim, president and CEO, said, "We greatly appreciate this recognition of Inovio's leadership and innovation in advancing the development of novel vaccines and analytical methods to assess vaccine effects. Our SynCon® vaccines administered with our proprietary electroporation delivery systems have generated best-in-class immune responses in our Phase I clinical trials for cervical dysplasia and HIV. The demonstration of antigen-specific CTL activity induced by Inovio's synthetic vaccines delivered by its proprietary CELLECTRA® electroporation system speaks well for our synthetic vaccine platform in general and in particular for our cancer vaccine programs."

Inovio has active therapeutic vaccine programs for HPV 16 and 18 associated cervical dysplasia/cancer (Phase II), chronic and acute myeloid leukemia (Phase II), prostate cancer (pre-clinical), hepatitis C virus (Phase II), and HIV (Phase I).

About Inovio Pharmaceuticals, Inc.

Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at [Devi essere iscritto e connesso per vedere questo link] .

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended June 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 [Devi essere iscritto e connesso per vedere questo link]: Jeff Richardson, Richardson & Associates 805-491-8313 [Devi essere iscritto e connesso per vedere questo link]
SOURCE Inovio Pharmaceuticals, Inc.


[Devi essere iscritto e connesso per vedere questo link]